{"id":"W2909359012","doi":"10.1016/j.carrev.2019.01.012","title":"CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?","year":2019,"lang":"en","type":"letter","venue":"Cardiovascular revascularization medicine","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Angina; Cardiology; Canadian Cardiovascular Society; Internal medicine; Tolerability; Revascularization; Adverse effect; TIMI; Unstable angina; Myocardial infarction; Percutaneous coronary intervention","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001757148,0.0008165772,0.002281024,0.0005677277,0.0002297552,0.00006115364,0.0003344547,0.001364958,0.0003265805],"category_scores_gemma":[0.001605067,0.0006904223,0.004670221,0.000428091,0.0001766483,0.0001846691,0.00006082247,0.0009949794,0.0002833096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003650968,"about_ca_system_score_gemma":0.0002768714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000026764,"about_ca_topic_score_gemma":3.209292e-7,"domain_scores_codex":[0.9953308,0.0002458949,0.001078094,0.001310737,0.001314418,0.0007201073],"domain_scores_gemma":[0.9945863,0.0007427784,0.000444705,0.002207681,0.001867946,0.0001505204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002923595,0.0002275992,0.00006525507,0.007410489,0.00386035,0.00007710233,0.00008636404,0.0003475653,0.0007146033,0.0000411291,0.9722284,0.01464879],"study_design_scores_gemma":[0.01167417,0.001875198,0.00008887775,0.001740536,0.005987593,0.0000846514,0.00002660639,0.002752511,0.0001447636,0.00009554209,0.9748506,0.0006789429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"methods","genre_gemma":"commentary","genre_scores_codex":[0.0005699616,0.09058265,0.7724715,0.1050841,0.005901795,0.02164028,0.0004988419,0.0005228135,0.002728137],"genre_scores_gemma":[0.00196736,0.04193306,0.02440679,0.4893866,0.1035114,0.007501857,0.1687881,0.00236598,0.1601388],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.7480647,"threshold_uncertainty_score":0.9999315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02359550798920124,"score_gpt":0.266304420104707,"score_spread":0.2427089121155058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}